Trial Bank
119 trials match
- NeuroDIP: Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
MOGADMSNMOSDNot a drug-phase studyNot yet recruiting
Institut National de la Santé Et de la Recherche Médicale, France · 2026 · 500 participants
- NFL OCT: Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
MSRelapsing and progressiveRunning, not recruiting
Centre Hospitalier Universitaire de Nīmes · 2019 · 200 participants
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
MSMS (type not specified)Phase 1Completed
ferumoxytol · National Institute of Neurological Disorders and Stroke (NINDS) · 2015 · 14 participants
- SurfSubQ: A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
MSRelapsing and progressiveRecruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 842 participants
- Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
MSMS (type not specified)Phase 2Recruiting
methylprednisolone, prednisone · National Institute of Neurological Disorders and Stroke (NINDS) · 2016 · 30 participants
- TIMELY-PLEX: Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
Optic neuritisPhase 3Recruiting
Mayo Clinic · 2025 · 382 participants
- TWEAK: TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyRecruiting
Assistance Publique Hopitaux De Marseille · 2023 · 50 participants
- CONTRASTOME: Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation
MSMS (type not specified)Not a drug-phase studyRunning, not recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 2025 · 60 participants
- A clinical proof-of-concept study to reduce smoldering inflammation in progressive MS
MSProgressive MSPhase 2Recruiting
istradefylline · University Of Turku · 2025 · 34 participants
- FZTA Pilot: This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
MSMS (type not specified)Recruiting
Washington University School of Medicine · 2025 · 80 participants
- SUN-627-MS201: A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
MSProgressive MSPhase 2Not yet recruiting
Sundance Biosciences Inc. · 2026 · 30 participants
- MoMo-NfL: Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
MSRelapsing MSNot a drug-phase studyRecruiting
Centre Hospitalier Universitaire de Nīmes · 2025 · 84 participants
- NL80681.078.22: lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder
NMOSDPhase 2Completed
imlifidase · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) · 2025 · 5 participants
- Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
MOGADMSNMOSDRecruiting
azathioprine · Beijing Tiantan Hospital · 2019 · 1,000 participants
- Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
MSMS (type not specified)Phase 1Recruiting
University of Alabama at Birmingham · 2019 · 120 participants
- Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
MSMS (type not specified)Phase 1Suspended
University of Alabama at Birmingham · 2021 · 120 participants
- SOSTOS: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
MSRelapsing and progressivePhase 4Running, not recruiting
ofatumumab · Novartis Pharmaceuticals · 2022 · 136 participants
- Smoldering Inflammation in MS
MSMS (type not specified)Recruiting
Washington University School of Medicine · 2024 · 25 participants
- RETIMUS: Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
MSOptic neuritisRelapsing and progressiveNot a drug-phase studyCompleted
Institut National de la Santé Et de la Recherche Médicale, France · 2020 · 50 participants
- Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
MSProgressive MSNot yet recruiting
Ondokuz Mayıs University · 2026 · 22 participants
- Impact of Exercise Training on Serum Neurofilament Light Chain (NfL), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis
MSRelapsing MSNot a drug-phase studyNot yet recruiting
Firat University · 2026 · 26 participants
- INFLANET: Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)
MSRelapsing MSNot a drug-phase studyRecruiting
Assistance Publique - Hôpitaux de Paris · 2025 · 41 participants
- FUSION: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
MSRelapsing and progressivePhase 2Completed
biib-091, diroximel fumarate · Biogen · 2023 · 127 participants
- MuTreg: In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
MSMS (type not specified)Not a drug-phase studyCompleted
Assistance Publique - Hôpitaux de Paris · 2023 · 67 participants
- INPSYSEP: Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis
MSRelapsing MSNot yet recruiting
University Hospital, Caen · 2026 · 150 participants
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
MSMS (type not specified)Recruiting
Brain Inflammation Collaborative · 2023 · 10,000 participants
- Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
MSRelapsing MSRecruiting
ofatumumab · Third Affiliated Hospital, Sun Yat-Sen University · 2023 · 80 participants
- AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
MSEarly (CIS/RIS)Phase 2Recruiting
natalizumab · Queen Mary University of London · 2022 · 40 participants
- ESPOIR2: Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research
MSMS (type not specified)Recruiting
Fondation Ophtalmologique Adolphe de Rothschild · 2023 · 200 participants
- SCOUT-MS: Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis
MSMS (type not specified)Recruiting
Fondation Ophtalmologique Adolphe de Rothschild · 2024 · 196 participants
- Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
MSRelapsing MSPhase 4Completed
Massachusetts General Hospital · 2020 · 22 participants
- RESEPTOR 5-HT7: Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis
MSMS (type not specified)Completed
Centre Hospitalier Régional d'Orléans · 2023 · 100 participants
- VIP-MODEL: VIsual Pathways Model in Neuro-inflammatory Disorders
Optic neuritisRecruiting
University Hospital, Lille · 2022 · 100 participants
- TACS-CI-IIDDs: Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
ADEMMSNMOSDNot a drug-phase studyRecruiting
Xuanwu Hospital, Beijing · 2025 · 128 participants
- Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSDNot yet recruiting
National and Kapodistrian University of Athens · 2025 · 40 participants
- MITOFATIGUE: Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
MSMS (type not specified)Enrolling by invitation
University Hospital, Martin · 2024 · 100 participants
- REtinal Markers In Neuroinflammatory Diseases ("REMIND")
MSMS (type not specified)Recruiting
University Hospital, Basel, Switzerland · 2024 · 500 participants
- PLAQ-MS: Multimodal Imaging of MS Reveals the Smoldering Inflammation
MSRelapsing and progressiveRunning, not recruiting
Turku University Hospital · 2019 · 40 participants
- Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
MSMS (type not specified)Phase 1Phase 2Completed
anakinra · National Institute of Neurological Disorders and Stroke (NINDS) · 2019 · 8 participants
- Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
ADEMMOGADMSNMOSDOptic neuritisTransverse myelitisRecruiting
University of Bern · 2020 · 500 participants
- Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
MSRelapsing MSPhase 4Recruiting
ozanimod · Azienda Ospedaliera Universitaria Integrata Verona · 2023 · 50 participants
- CARTinNS: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
MOGADMSNMOSDRelapsing and progressiveEarly phase 1Recruiting
cyclophosphamide anhydrous · Tongji Hospital · 2020 · 36 participants
- Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation
MSMS (type not specified)Status unknown
Neuromed IRCCS · 2022 · 500 participants
- A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
MSRelapsing MSPhase 4Completed
ofatumumab · Novartis Pharmaceuticals · 2021 · 63 participants
- Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
ADEMMOGADMSNMOSDNot a drug-phase studyRecruiting
Tongji Hospital · 2024 · 250 participants
- Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
MSMS (type not specified)Phase 2Status unknown
tolebrutinib · National Institute of Neurological Disorders and Stroke (NINDS) · 2021 · 12 participants
- Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
ADEMMOGADMSNMOSDEarly (CIS/RIS)Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2024 · 450 participants
- GR-2021-12373041: Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis
MSProgressive MSPhase 4Recruiting
siponimod · Azienda Ospedaliera Universitaria Integrata Verona · 2023 · 40 participants
- Influence of Anaesthesia Type on Multiple Sclerosis Relapse
MSMS (type not specified)Completed
Varazdin General Hospital · 2012 · 56 participants
- Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program Patients With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyStatus unknown
Universidad Europea de Madrid · 2024 · 32 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error